Dow Jones

39 908,00

0,88%

DAX

Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.

S'inscrire

Accueil
Investir
Actions
L'Europe
EU
Oxurion NV (OXUR)
Oxurion NV (OXUR) Actualités

OXUR

Oxurion NV (OXUR)

Oxurion NV

De:

Actualités Réglementées

Mots clefs:

Trier par:

Actualités Non-réglementées

Showing the most relevant articles for your search:EU:OXUR

1 2 3 4 5 Suivant >>

Date	Heure	Source	Titre	Symbole	Société
14/05/2024	19h00	GlobeNewswire Inc.	Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas	EU:OXUR	Oxurion NV
13/05/2024	19h00	GlobeNewswire Inc.	Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC	EU:OXUR	Oxurion NV
06/05/2024	18h00	GlobeNewswire Inc.	Important Advances in Oxurion's R&D Program on Geographic Atrophy secondary to AMD	EU:OXUR	Oxurion NV
15/04/2024	17h16	GlobeNewswire Inc.	Publication Annual Report – Annual Shareholders' Meeting	EU:OXUR	Oxurion NV
11/04/2024	19h00	GlobeNewswire Inc.	Oxurion Receives Transparency Notifications from Atlas Special Opportunities LLC	EU:OXUR	Oxurion NV
10/04/2024	19h00	GlobeNewswire Inc.	Oxurion Receives EUR 450,000 in the framework of the Atlas Funding Program : Eleventh tranche fully issued and paid-up	EU:OXUR	Oxurion NV
05/04/2024	14h00	GlobeNewswire Inc.	Postponement Annual Shareholders Meeting - Amendment financial calendar	EU:OXUR	Oxurion NV
27/03/2024	19h00	GlobeNewswire Inc.	Information on the Total Number of Voting Rights (Denominator) following Conversion Notices from Atlas - Amended version	EU:OXUR	Oxurion NV
26/03/2024	19h00	GlobeNewswire Inc.	Information on the Total Number of Voting Rights (Denominator) following Conversion Notices from Atlas	EU:OXUR	Oxurion NV
25/03/2024	19h10	GlobeNewswire Inc.	OXURION announces its presence at the Paris SmallCap event on March 28, 2024.	EU:OXUR	Oxurion NV
05/03/2024	19h00	GlobeNewswire Inc.	Oxurion Receives EUR 300,000 in the framework of the Atlas Funding Program Tenth tranche fully issued and paid-up	EU:OXUR	Oxurion NV
22/01/2024	22h02	GlobeNewswire Inc.	Oxurion Announces New Strategic Orientation to De-risk and Diversify	EU:OXUR	Oxurion NV
28/12/2023	21h15	GlobeNewswire Inc.	Oxurion Avoids Bankruptcy, Announces Board and Management Changes and Enters into Binding Letter of Intent with its Main Creditor Atlas	EU:OXUR	Oxurion NV
20/11/2023	07h00	GlobeNewswire Inc.	Oxurion Discloses Topline Data from KALAHARI Phase 2, Part B Trial of Novel PKal Inhibitor THR-149 in Diabetic Macular Edema	EU:OXUR	Oxurion NV
16/11/2023	19h00	GlobeNewswire Inc.	Oxurion Receives EUR 1.0 Million under Amended Atlas Funding Program Total of EUR 3.5 Million in Unconditional Funding Allowing Company to Reach Topline Data from KALAHARI Trial This Year	EU:OXUR	Oxurion NV
25/10/2023	08h00	GlobeNewswire Inc.	Oxurion Receives EUR 1.5 Million under Amended Atlas Funding Program; Total of EUR 3.5 Million in Unconditional Funding Allowing Company to Achieve Topline Data from KALAHARI Trial	EU:OXUR	Oxurion NV
29/09/2023	19h00	GlobeNewswire Inc.	Oxurion Publishes First Half 2023 Results	EU:OXUR	Oxurion NV
18/09/2023	08h04	GlobeNewswire Inc.	Oxurion Receives First EUR 1 Million under Amended Atlas Funding Program	EU:OXUR	Oxurion NV
11/09/2023	08h00	GlobeNewswire Inc.	Oxurion Announces Key Amendments to Atlas and Kreos/Pontifax Agreements Enabling KALAHARI Trial to Progress to Topline Results in 2023	EU:OXUR	Oxurion NV
11/08/2023	08h08	GlobeNewswire Inc.	Oxurion Receives Funding of EUR One Million under Atlas Special Opportunities LLC (Atlas) Funding Program	EU:OXUR	Oxurion NV
26/07/2023	19h00	GlobeNewswire Inc.	Oxurion Receives Transparency Notifications from Atlas Special Opportunities LL	EU:OXUR	Oxurion NV
25/07/2023	08h00	GlobeNewswire Inc.	Oxurion Receives Upfront Payment of $400,000 Following Oncurious Asset License by VIB	EU:OXUR	Oxurion NV
14/07/2023	19h00	GlobeNewswire Inc.	Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC	EU:OXUR	Oxurion NV
15/06/2023	19h02	GlobeNewswire Inc.	Oxurion Issues EUR 1.0 million in Bonds for Tranche 3 of the Funding Program with Atlas Special Opportunities LLC	EU:OXUR	Oxurion NV
12/06/2023	20h00	GlobeNewswire Inc.	Oxurion Receives Transparency Notifications from Atlas Special Opportunities LLC	EU:OXUR	Oxurion NV
12/06/2023	08h00	GlobeNewswire Inc.	Oxurion Finalizes Enrollment in KALAHARI Phase 2, Part B Trial of Novel PKal Inhibitor THR-149 in Diabetic Macular Edema	EU:OXUR	Oxurion NV
09/06/2023	08h00	GlobeNewswire Inc.	Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from ATLAS	EU:OXUR	Oxurion NV
05/06/2023	19h00	GlobeNewswire Inc.	Oxurion Announces Results of the Extraordinary Shareholders’ Meeting of 22 May 2023	EU:OXUR	Oxurion NV
01/06/2023	08h00	GlobeNewswire Inc.	Oxurion to Participate in Upcoming Conferences	EU:OXUR	Oxurion NV
25/05/2023	21h00	GlobeNewswire Inc.	Oxurion Reaches Enrollment Target in KALAHARI Phase 2, Part B Trial of Novel PKal Inhibitor THR-149 in Diabetic Macular Edema	EU:OXUR	Oxurion NV